The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Between 2026 And 2030?

The deoxyribonucleic acid (DNA) sequencing in drug discovery market has experienced swift expansion in recent years. It is projected to grow from $8.46 billion in 2025 to $9.49 billion in 2026, at a compound annual growth rate (CAGR) of 12.3%. Historically, this growth can be attributed to factors like heightened investment in genomic research, the widening of pharmaceutical R&D pipelines, the accessibility of high-throughput sequencing platforms, an increasing emphasis on personalized medicine, and advancements in sequencing accuracy and speed.

The deoxyribonucleic acid (dna) sequencing in drug discovery market size anticipates substantial expansion over the upcoming years. This market is projected to reach $15.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. This projected growth is driven by several factors, including the increasing integration of AI-driven genomic analysis, a heightened demand for targeted therapeutic solutions, the broadening scope of pharmacogenomics applications, the expanding utility of sequencing in early-stage drug screening processes, and enhanced collaborations between pharmaceutical and biotechnology companies. Key trends expected during this period involve a greater application of next-generation sequencing for target identification, the increasing embrace of single-cell sequencing methodologies, a deeper incorporation of bioinformatics within drug discovery efforts, the expansion of research initiatives in precision medicine, and a heightened emphasis on drug development guided by biomarkers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33087&type=smp

What Market Drivers Are Helping Shape The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Expansion?

The increasing need for individualized medicine is anticipated to fuel the expansion of deoxyribonucleic acid (DNA) sequencing within the drug discovery market in the future. Individualized medicine is defined as a healthcare strategy that customizes the prevention, diagnosis, and treatment of diseases based on a person’s genetic profile, lifestyle choices, and environmental influences. The growing interest in personalized medicine largely stems from progress in genomics and molecular diagnostics, which facilitate the accurate detection of genetic and molecular variations between individuals, thereby enabling the customization of therapies for enhanced efficacy and fewer adverse reactions. Deoxyribonucleic acid (DNA) sequencing supports personalized medicine through the detection of genetic differences specific to each patient, which in turn permits the creation of focused treatments, improved drug choices, and better treatment outcomes while minimizing negative impacts. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit, showed that in 2023, the Food and Drug Administration (FDA) authorized 16 novel personalized therapies for patients with rare diseases, an increase from six in 2022. Among the new personalized treatments cleared in 2023 were also seven medications for cancer and three for various other conditions. Consequently, the increased need for personalized medicine is a key factor propelling the expansion of deoxyribonucleic acid (DNA) sequencing within the drug discovery market.

What Segment Types Are Included In The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Analysis?

The deoxyribonucleic acid (dna) sequencing in drug discovery market covered in this report is segmented –

1) By Product Type: Instruments; Consumables

2) By Workflow: Sample Preparation; Sequencing

3) By Technology Type: Sanger Sequencing; Next-Generation Sequencing (NGS)

4) By Application: Drug Discovery; Pharmacogenomics

5) By End-User: Pharmaceutical Companies; Biotechnology Firms

Subsegments:

1) By Instruments: Sequencing Systems; Sample Preparation Systems; Detection And Imaging Systems; Automation And Robotics Systems; Data Analysis Hardware

2) By Consumables: Sequencing Reagents; Library Preparation Kits; Sample Collection Kits; Flow Cells; Quality Control Reagents

Which Trends Are Influencing The Direction Of The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

Major companies engaged in deoxyribonucleic acid (DNA) sequencing for the drug discovery market are prioritizing the development of sophisticated solutions, including high-resolution DNA methylation sequencing assays, to expedite biomarker discovery and precision drug development. These high-resolution DNA methylation sequencing assays are advanced genomic methodologies that accurately map DNA methylation at single-base or near single-base resolution across the entire genome. This allows for an in-depth assessment of epigenetic changes that govern gene activity, thereby aiding a precise understanding of disease biology and the identification of potential drug targets. As an illustration, in April 2025, EpiCypher Inc., a US-based epigenetics company, launched CUTANA mCUT&RUN and Multiomic CUT&RUN. These innovative DNA methylation sequencing assays were designed to provide high-resolution methylation profiling with notably reduced sequencing costs and lower sample input requirements. Such assays enable researchers to concurrently examine DNA methylation and chromatin features, offering more profound multiomic insights into gene regulation mechanisms. These advancements in assay technology facilitate quicker and more cost-efficient target identification and validation, consequently accelerating the drug discovery and development timeline.

Which Companies Form The Competitive Landscape Of The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

Major companies operating in the deoxyribonucleic acid (dna) sequencing in drug discovery market are Thermo Fisher Scientific Inc., Eurofins Genomics GmbH, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., BGI Genomics, Azenta Life Sciences, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Element Biosciences Inc., Macrogen Inc., Ultima Genomics Inc., SOPHiA GENETICS SA, ProPhase Labs Inc., Singular Genomics Systems Inc., Psomagen Inc., and QitanTech Co Ltd.

Access The Complete Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Report:

https://www.thebusinessresearchcompany.com/report/deoxyribonucleic-acid-dna-sequencing-in-drug-discovery-market-report

Which Region Accounts For The Highest Share Of The Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market?

North America was the largest region in the deoxyribonucleic acid (DNA) sequencing in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxyribonucleic acid (dna) sequencing in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model